A fatal case of triple coinfection: COVID-19, HIV and Tuberculosis

Ortiz-Martínez, Yeimer; Mogollón-Vargas, Julie Melissa; López-Rodríguez, Marggie; Rodríguez-Morales, Alfonso J.

doi:10.1016/j.tmaid.2021.102129

Cited by 11 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One meta-analysis showed that co-infection of tuberculosis is a significant poor prognostic factor among COVID-19-infected patients [ 12 ]. Also, it was reported that a fatal case of rapidly progressed extrapulmonary tuberculosis was triggered by COVID-19 infection in poor-adherence HIV-1-infected patient (CD4# 105/μL at COVID-19 diagnosis) [ 13 ]. Immuno-modulating effects of COVID-19 on pre-existing infectious diseases, such as tuberculosis, have been analyzed by biological models like 3D organoids [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Unmasking latent extrapulmonary tuberculosis with newly diagnosed HIV-1 infection in a COVID-19 patient with prolonged fever

Hirata

Watanabe

Sasaki³

et al. 2022

Oxford Medical Case Reports

View full text Add to dashboard Cite

Prolonged fever is a common symptom of COVID-19 infection. However, other febrile diseases continue during the pandemic. Herein, we report a COVID-19-infected patient with prolonged fever despite the lack of oxygen requirement, who was finally diagnosed with tuberculotic lymphadenitis and HIV-1 infection. All symptoms improved rapidly after the initiation of antituberculosis medications. Tuberculosis is an important differential diagnosis for patients with prolonged fever during the COVID-19 pandemic. It is possible that COVID-19 infection could serve to unmask latent infections via a cytokine storm.

show abstract

Section: Discussionmentioning

confidence: 99%

Unmasking latent extrapulmonary tuberculosis with newly diagnosed HIV-1 infection in a COVID-19 patient with prolonged fever

Hirata

Watanabe

Sasaki³

et al. 2022

Oxford Medical Case Reports

View full text Add to dashboard Cite

show abstract

“…Os medicamentos antituberculosos (principalmente a rifampicina) são poderosos indutores enzimáticos, que podem reduzir a eficácia da cloroquina em paciente. E a imunodepressão induzida pela infecção por HIV pode tornar a infecção por COVID-19 grave e com maior risco de mortalidade de pacientes internados por COVID-19 em pessoas com HIV que não estão em TARV, com aumento da imunossupressão associada a alta carga viral do HIV [14,29].…”

Section: Métodounclassified

Covid-19, Hiv E Tuberculose: Riscos E Ameaças Da Coinfecção Tripla

Samuel¹,

Nhatsave²,

Monjane³

2022

RECIMA21

View full text Add to dashboard Cite

O cruzamento de doenças de COVID-19, HIV e Tuberculose em países com uma alta carga de infecções por HIV e TB apresenta vários desafios à saúde pública do século XXI, até então nunca descrita, é potencialmente fatal. Objectivo: avaliar os aspectos diagnósticos e prognósticos de pacientes coinfectados com COVID-19, HIV e tuberculose. Metodologia: Trata-se de um estudo de revisão integrativa de literatura, de carácter descritivo e de abordagem qualitativa, nas bases de dados Google Scholar, PubMed, SciELO e LILACS, utilizando os descritores “COVID-19 e co-infecção; COVID-19, HIV e Tuberculose”. Resultados: Foram incluídos 6 artigos. A maioria dos pacientes com co-infecção tripla foi do sexo masculino, com média de idade de 43.5 anos. Os sintomas mais relatados foram febre, tosse, cefaleia, mialgia e astenia. As principais alterações laboratoriais incluíram CD4 com níveis diminuído, alta carga viral, linfopenia, trombocitopenia, Hemoglobina com níveis diminuído, níveis elevados de proteína C reativa, velocidade de hemossedimentação aumentada, elevação de D-dímero e hiperferritinemia. Achados imaginológicos como infiltrados apical esquerdo, opacidades irregulares peri-hilares, cavitações, empiema pleural, vidro fosco e opacidades nodulares foram frequentes. A letalidade foi de 2,6%. Conclusão: O presente estudo mostrou que os casos da COVID-19 associados ao HIV/TB são mais comuns em homens e observou-se uma tendência dos pacientes coinfectados a evoluírem com quadro moderado ou grave, incluindo necessidade de internamento. Por isso é fundamental que os profissionais de saúde estejam actualizados e capacitados no manejo de pacientes com co-infecção HIV/TB aquando da sua associação à infecção por COVID-19 com vista a melhoria de prognóstico

show abstract

“…[31] reported a case of triple co-infection of nCOVID-19, HIV, and TB in which the patient recovered after getting intime medical attention. (ii) Ortiz-Martínez et al [32] reported a fatal death case of a female patient with triple co-infection (HIV/TB/SARS-CoV-2). The nCOVID-19 infection puts TB and HIV responses in jeopardy.…”

Section: Introductionmentioning

confidence: 99%

Tuberculosis and HIV responses threatened by nCOVID-19: A situation prompting an in silico investigation of reported MbtA inhibitors for combined inhibition of SARS-CoV-2 and HIV-TB co-infection

Rakshit

Jayaprakash

2022

Struct Chem

View full text Add to dashboard Cite

The menace of infectious diseases has constantly been a reason of concern for humankind since time immemorial. As evident by the name, infectious diseases can infect a huge population within a short period, leading to an eruption of pandemics and epidemics. The present human era is fortunate enough to have a wide array of readily available drugs that help cure and prevent various diseases. Moreover, the scientific community has always responded to the needs of society through its drug discovery and development programs. The co-existence of multiple diseases calls forth the scientific community to design and develop drugs that could have a broad spectrum of activity. In this perspective, our goal was to investigate the potential of reported MbtA inhibitors (antitubercular molecules) in inhibiting HIV-1 RT and nCovid-19-RdRp and eventually leading to the identification of a multi-targeted ligand (triple co-infection inhibitor). In this study, the primary success was attained by capitalizing on the structure-based virtual screening drug discovery approach. Results were quite promising. Molecular docking results showed that GV17 interacted strongly with the active site residues of both the target proteins (HIV-1 RT and nCOVID-19-RdRp). Moreover, the docking score of GV17 was more than that of the internal ligands of both the target proteins, which indicates a firm binding. Molecular dynamics further validated these results as identical amino acid residues were observed in the protein's docked pose with the ligand. The detailed atomic interactions of ligand GV17 with the protein residues have been discussed. Overall, the protein-ligand complexes remained stable throughout the simulation, and the system's backbone fluctuations were modest. MM-GBSA analysis revealed free binding energy of − 72.30 ± 7.85 kcal/mol and − 65.40 ± 7.25 kcal/mol for 1RT2 and 7BV2, respectively. The more negative binding energy indicates a stronger affinity of GV17 with both the receptors. GV17 also gave satisfactory predictive in silico ADMET results. Overall, this computational study identified GV17 as a potential HIT molecule and findings can open up a new avenue to explore and develop inhibitors against nCOVID-19-HIV-TB triple-infections.

show abstract

A fatal case of triple coinfection: COVID-19, HIV and Tuberculosis

Cited by 11 publications

References 6 publications

Unmasking latent extrapulmonary tuberculosis with newly diagnosed HIV-1 infection in a COVID-19 patient with prolonged fever

Unmasking latent extrapulmonary tuberculosis with newly diagnosed HIV-1 infection in a COVID-19 patient with prolonged fever

Covid-19, Hiv E Tuberculose: Riscos E Ameaças Da Coinfecção Tripla

Tuberculosis and HIV responses threatened by nCOVID-19: A situation prompting an in silico investigation of reported MbtA inhibitors for combined inhibition of SARS-CoV-2 and HIV-TB co-infection

Contact Info

Product

Resources

About